We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Reduced Antioxidant Protection Leads to Neuron Loss in Parkinson's Disease

By LabMedica International staff writers
Posted on 13 Mar 2016
Lack of antioxidant protection in brain cells due to mutations that prevent the expression of the protein encoded by the oncogene DJ-1 (also known as Parkinson protein 7 or PARK7) has been linked to premature aging of neurons in Parkinson's disease patients.

The oncogene DJ-1 was identified originally as a suppressor of PTEN (phosphatase and tensin homolog), and loss-of-function mutations have been described as a causative factor in Parkinson's disease (PD). More...
While it was known that DJ-1 had an important function in cellular antioxidant responses, its role in the central metabolism of neurons remained to be clarified.

Investigators at the University of Luxembourg (Esch-sur-Alzette, Luxembourg) applied stable isotope assisted metabolic profiling to investigate the effect of a functional loss of DJ-1.

They reported in the February 1, 2016, online edition of the journal Neurobiology of Disease that DJ-1 deficient neuronal cells exhibited decreased glutamine influx and reduced serine biosynthesis. These two metabolic pathways provide the precursors glutamate, serine, and glycine for de novo synthesis of glutathione. In line with these metabolic flux changes, the investigators observed decreased glutathione levels and an impaired antioxidant response in DJ-1 deficient cells.

In addition, DJ-1 deficient mouse microglia showed a weak but constitutive pro-inflammatory activation. The combined effects of altered antioxidant metabolism and constitutive activation of glia cells raised the susceptibility of dopamine-producing neurons towards degeneration in patients harboring mutated DJ-1.

"Normally, microglial cells are only activated when something in the brain needs to be cleaned up, for instance during inflammation," said senior author Dr. Karsten Hiller, head of the metabolomics group at the University of Luxembourg. "However, if these cells are constantly active, as we discovered happens with the DJ-1 defect, this weakens the underlying neurons. We need the right amount of DJ-1. While in some forms of cancer there is too much DJ-1, in this case of Parkinson's disease, neurons do not have enough DJ-1 and die off."

Related Links:

University of Luxembourg



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.